The Impact of Different Anticoagulant Therapy on Hemorrhage and Coagulation After Thoracic Surgery
NCT ID: NCT01267305
Last Updated: 2014-04-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
362 participants
INTERVENTIONAL
2011-01-31
2013-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of the Effectiveness of Prophylactic LMWH by Thromboelastography
NCT06484231
Robotic Surgery Via Bilateral Axillo-breast Approach for Relatively Low-risk Papillary Thyroid Carcinoma With Lateral Cervical Lymph Node Metastasis: a Safe and Effective Cosmetic Procedure in the Context of Prevalent Thyroid Ultrasound Screening
NCT07229859
Hemodynamic and Inflammatory Responses in Thoracic Surgery
NCT02647775
A Retrospective Analysis of Statin Use and Outcome After Thoracic Cancer Surgery
NCT01169051
Intraoperative Pathologic Evaluation of Central Lymph Nodes in Papillary Thyroid Carcinoma
NCT07066644
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
lung lmwh1
use LMWH once daily after lung resection
Nadroparin Calcium
4100AxaIU IH qd(8AM) after operation
lung lmwh2
use LMWH twice daily after lung resection
Nadroparin Calcium
4100AxaIU IH q12h(8Am,8Pm) after operation
lung Fondaparinux
use Fondaparinux once daily after lung resection
Fondaparinux
2.5mg IH qd(8AM) after operation
eso lmwh1
use LMWH once daily after esophagectomy
Nadroparin Calcium
4100AxaIU IH qd(8AM) after operation
eso lmwh2
use LMWH twice daily after esophagectomy
Nadroparin Calcium
4100AxaIU IH q12h(8Am,8Pm) after operation
eso Fondaparinux
use Fondaparinux once daily after esophagectomy
Fondaparinux
2.5mg IH qd(8AM) after operation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fondaparinux
2.5mg IH qd(8AM) after operation
Nadroparin Calcium
4100AxaIU IH qd(8AM) after operation
Nadroparin Calcium
4100AxaIU IH q12h(8Am,8Pm) after operation
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* clinical diagnosis of lung carcinoma and planned for lung resection
* general anesthesia combined with epidural anesthesia
Exclusion Criteria
* anticoagulating or antiplatelet history before surgery
* low blood platelets count
* hemorrhagic disease
* cerebral hemorrhage
* cerebral,spinal,ophthalmologic operation history
* peptic ulcer
* bleeding\>400ml in operation
* bleeding\>100ml/h after operation
* blood transfusion in or after operation
* severe renal or liver disfunction
* severe hypertension
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Zhongshan Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ming Zhong
department of anesthesiology and surgical intensive care unit
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lizhen Xuan
Role: PRINCIPAL_INVESTIGATOR
Shanghai Zhongshan Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zhongshan Hospital
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SICUTEG-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.